149 related articles for article (PubMed ID: 11758090)
1. [Which properties make a neuroleptic "atypical"?].
Gründer G; Vernaleken I; Benkert O
Nervenarzt; 2001 Nov; 72(11):833-43. PubMed ID: 11758090
[TBL] [Abstract][Full Text] [Related]
2. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
3. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
Stahl SM
J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
[TBL] [Abstract][Full Text] [Related]
4. [Atypical neuroleptics, pharmacology and clinical importance].
Klages U; Hippius H; Müller-Spahn F
Fortschr Neurol Psychiatr; 1993 Nov; 61(11):390-8. PubMed ID: 7903656
[TBL] [Abstract][Full Text] [Related]
5. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T
J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351
[TBL] [Abstract][Full Text] [Related]
6. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
[TBL] [Abstract][Full Text] [Related]
8. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
9. Receptor pharmacology of neuroleptics: relation to clinical effects.
Richelson E
J Clin Psychiatry; 1999; 60 Suppl 10():5-14. PubMed ID: 10340682
[TBL] [Abstract][Full Text] [Related]
10. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy.
Sumiyoshi T; Suzuki K; Sakamoto H; Yamaguchi N; Mori H; Shiba K; Yokogawa K
Neuropsychopharmacology; 1995 Feb; 12(1):57-64. PubMed ID: 7766287
[TBL] [Abstract][Full Text] [Related]
11. The importance of serotonin-dopamine interactions in the action of clozapine.
Meltzer HY
Br J Psychiatry Suppl; 1992 May; (17):22-9. PubMed ID: 1358125
[TBL] [Abstract][Full Text] [Related]
12. [Flupenthixol--a partial atypical neuroleptic?].
Kühn KU; Meyer K; Maier W
Fortschr Neurol Psychiatr; 2000 Apr; 68 Suppl 1():S38-41. PubMed ID: 10907612
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.
Asproni B; Pau A; Bitti M; Melosu M; Cerri R; Dazzi L; Seu E; Maciocco E; Sanna E; Busonero F; Talani G; Pusceddu L; Altomare C; Trapani G; Biggio G
J Med Chem; 2002 Oct; 45(21):4655-68. PubMed ID: 12361392
[TBL] [Abstract][Full Text] [Related]
14. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
Bortolozzi A; Díaz-Mataix L; Toth M; Celada P; Artigas F
Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
[TBL] [Abstract][Full Text] [Related]
15. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacology of neuroleptics: focus on new generation compounds.
Richelson E
J Clin Psychiatry; 1996; 57 Suppl 11():4-11. PubMed ID: 8941166
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
Markianos M; Hatzimanolis J; Lykouras L
Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
[TBL] [Abstract][Full Text] [Related]
18. Interaction between aminergic systems in mesolimbic structures: the importance of 5-HT2, D2 and D1 receptors in the olfactory tubercle for the atypical profile of neuroleptics.
Cools AR; Prinssen E; Ellenbroek BA
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():618A-619A. PubMed ID: 1354068
[TBL] [Abstract][Full Text] [Related]
19. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain?
Westerink BH
Eur J Pharmacol; 2002 Nov; 455(1):1-18. PubMed ID: 12433589
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
